SPSB1, a novel negative regulator of the TGF-beta signaling pathway targeting the type II receptor
Details
Publication Year 2016-07-17,Volume 290,Issue #29,Page 17894-17908
Journal Title
Journal of Biological Chemistry
Publication Type
Journal Article
Abstract
Appropriate cellular signaling is essential to control cell proliferation, differentiation and cell death. Aberrant signaling can have devastating consequences and lead to disease states including cancer. The transforming growth factor-beta (TGF-beta) signaling pathway is a prominent signaling pathway that has been tightly regulated in normal cells while its deregulation strongly correlates with the progression of human cancers. The regulation of the TGF-beta signaling pathway involves a variety of physiological regulators. Many of these molecules act to alter the activity of Smad proteins. In contrast, the number of molecules known to affect TGF-beta signaling pathway at the receptor level is relatively low and there are no known direct modulators for the TGF-beta type II receptor (TbetaRII). Here we identify SPSB1 (a SPRY domain-containing SOCS box protein) as a novel regulator of the TGF-beta signaling pathway. SPSB1 negatively regulates TGF-beta signaling pathway through its interaction with both endogenous and over-expressed TbetaRII (and not TbetaRI) via its SPRY domain. As such, TbetaRII and SPSB1 colocalize on the cell membrane. SPSB1 maintains TbetaRII at a low level by enhancing the ubiquitination levels and degradation rates of TbetaRII through its SOCS box. More importantly, silencing SPSB1 by siRNA results in enhanced TGF-beta signaling and migration and invasion of tumor cells.
Publisher
ASMB
Research Division(s)
Inflammation; Systems Biology And Personalised Medicine
PubMed ID
26032413
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2015-06-15 09:53:28
Last Modified: 2016-05-05 11:03:01
An error has occurred. This application may no longer respond until reloaded. Reload 🗙